Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib in Advanced Stomach and Gastroesophageal Junction Cancer
NCT00032123Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Jun 2002
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of erlotinib in gastric cancer (GC) and gastroesophageal junction cancer (2 arms), sponsored by SWOG Cancer Research Network. Primary endpoints: Overall Response Rate up to 3 years, Frequency and severity of toxic effects up to 3 years and 2 more. Started Jun 2002; status: completed.
02
Drugs
erlotinib
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT00032123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00032123.